Early-Stage Pharmacological Validation of Novel Targets and Accompanying Pre-Therapeutic Leads for Diseases of Interest to the NIDDK (R01)

 

The overarching goal of this Funding Opportunity Announcement (FOA) is to promote translation of basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase drug discovery and development efforts in areas relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematology, and specific aspects of cystic fibrosis. For additional information on disease areas of interest to the NIDDK, please see http://www2.niddk.nih.gov/Research/ .

Active PAR-13-007 Agency: Department of Health and Human Services
Office: National Institutes of Health Grant Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 03/07/2016 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/pa-files/PAR-13-007.html FBOWebmaster@OD.NIH.GOV $0.00 Awards up to $500,000.00